{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T12:41:32Z","timestamp":1770295292139,"version":"3.49.0"},"reference-count":48,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"unspecified","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Kids Operating Room"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2022,4,13]]},"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Childhood cancer is a leading cause of death. It is unclear whether the COVID-19 pandemic has impacted childhood cancer mortality. In this study, we aimed to establish all-cause mortality rates for childhood cancers during the COVID-19 pandemic and determine the factors associated with mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Prospective cohort study in 109 institutions in 41 countries. Inclusion criteria: children &lt;18 years who were newly diagnosed with or undergoing active treatment for acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, Hodgkin lymphoma, retinoblastoma, Wilms tumour, glioma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, medulloblastoma and neuroblastoma. Of 2327 cases, 2118 patients were included in the study. The primary outcome measure was all-cause mortality at 30 days, 90 days and 12 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All-cause mortality was 3.4% (n=71\/2084) at 30-day follow-up, 5.7% (n=113\/1969) at 90-day follow-up and 13.0% (n=206\/1581) at 12-month follow-up. The median time from diagnosis to multidisciplinary team (MDT) plan was longest in low-income countries (7\u2009days, IQR 3\u201311). Multivariable analysis revealed several factors associated with 12-month mortality, including low-income (OR 6.99 (95% CI 2.49 to 19.68); p&lt;0.001), lower middle income (OR 3.32 (95% CI 1.96 to 5.61); p&lt;0.001) and upper middle income (OR 3.49 (95% CI 2.02 to 6.03); p&lt;0.001) country status and chemotherapy (OR 0.55 (95% CI 0.36 to 0.86); p=0.008) and immunotherapy (OR 0.27 (95% CI 0.08 to 0.91); p=0.035) within 30 days from MDT plan. Multivariable analysis revealed laboratory-confirmed SARS-CoV-2 infection (OR 5.33 (95% CI 1.19 to 23.84); p=0.029) was associated with 30-day mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Children with cancer are more likely to die within 30 days if infected with SARS-CoV-2. However, timely treatment reduced odds of death. This report provides crucial information to balance the benefits of providing anticancer therapy against the risks of SARS-CoV-2 infection in children with cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgh-2022-008797","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T12:31:13Z","timestamp":1666182673000},"page":"e008797","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Twelve-month observational study of children with cancer in 41 countries during the COVID-19 pandemic"],"prefix":"10.1136","volume":"7","author":[{"name":"Global Health Research Group on Children\u2019s Non-Communicable Diseases Collaborative","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,10,19]]},"reference":[{"key":"2025072913330721000_7.10.e008797.1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.296.6633.1372"},{"key":"2025072913330721000_7.10.e008797.2","first-page":"156","article-title":"Advances in paediatric cancer treatment","volume":"3","author":"Saletta","year":"2014","journal-title":"Transl Pediatr"},{"key":"2025072913330721000_7.10.e008797.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70010-X"},{"key":"2025072913330721000_7.10.e008797.4","unstructured":"SEER Statistics . Cancer statistics review, 1975-2015. Available: https:\/\/seer.cancer.gov\/archive\/csr\/1975_2015\/ [Accessed 02 Oct 2020]."},{"key":"2025072913330721000_7.10.e008797.5","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(18)30761-7","article-title":"Childhood cancer burden: a review of global estimates","volume":"20","author":"Bhakta","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025072913330721000_7.10.e008797.6","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2352-4642(19)30238-X","article-title":"Fighting childhood cancer with data","volume":"3","year":"2019","journal-title":"Lancet Child Adolesc Health"},{"key":"2025072913330721000_7.10.e008797.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33326-3"},{"key":"2025072913330721000_7.10.e008797.8","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw4892"},{"key":"2025072913330721000_7.10.e008797.9","doi-asserted-by":"crossref","unstructured":"Gupta S , Howard SC , Hunger SP . Treating Childhood Cancer in Low- and Middle-Income Countries. In: Disease Control Priorities, Third Edition (Volume 3): Cancer. The World Bank, 2015: 121\u201346.","DOI":"10.1596\/978-1-4648-0349-9_ch7"},{"key":"2025072913330721000_7.10.e008797.10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23205"},{"key":"2025072913330721000_7.10.e008797.11","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(19)31052-9","article-title":"The Lancet Commission on diagnostics: advancing equitable access to diagnostics","volume":"393","author":"Wilson","year":"2019","journal-title":"Lancet"},{"key":"2025072913330721000_7.10.e008797.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70194-3"},{"key":"2025072913330721000_7.10.e008797.13","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.17.00175"},{"key":"2025072913330721000_7.10.e008797.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00223-5"},{"key":"2025072913330721000_7.10.e008797.15","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.17.00175"},{"key":"2025072913330721000_7.10.e008797.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70008-1"},{"key":"2025072913330721000_7.10.e008797.17","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e318249aa98"},{"key":"2025072913330721000_7.10.e008797.18","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S1470-2045(20)30022-X","article-title":"Sustainable care for children with cancer: a Lancet oncology Commission","volume":"21","author":"Atun","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025072913330721000_7.10.e008797.19","unstructured":"World Health Organization . WHO global initiative for childhood cancer: an overview; 2018."},{"key":"2025072913330721000_7.10.e008797.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017"},{"key":"2025072913330721000_7.10.e008797.21","unstructured":"World Health Organization . WHO Director-General\u2019s opening remarks at the media briefing on COVID-19 - 11 March 2020. Available: https:\/\/www.who.int\/dg\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020 [Accessed 03 May 2020]."},{"key":"2025072913330721000_7.10.e008797.22","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/s41416-020-01181-0","article-title":"Severity of COVID-19 in children with cancer: report from the United Kingdom paediatric coronavirus cancer monitoring project","volume":"124","author":"Millen","year":"2021","journal-title":"Br J Cancer"},{"key":"2025072913330721000_7.10.e008797.23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30339-0"},{"key":"2025072913330721000_7.10.e008797.24","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/S1470-2045(21)00454-X","article-title":"Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study","volume":"22","author":"Mukkada","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025072913330721000_7.10.e008797.25","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S2352-4642(21)00031-6","article-title":"Global effect of the COVID-19 pandemic on paediatric cancer care: a cross-sectional study","volume":"5","author":"Graetz","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"2025072913330721000_7.10.e008797.26","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(20)30280-1","article-title":"Early impact of the COVID-19 pandemic on paediatric cancer care in Latin America","volume":"21","author":"Vasquez","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025072913330721000_7.10.e008797.27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-045679"},{"key":"2025072913330721000_7.10.e008797.28","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20910"},{"key":"2025072913330721000_7.10.e008797.29","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/S1470-2045(15)00539-2","article-title":"Paediatric cancer stage in population-based cancer registries: the Toronto consensus principles and guidelines","volume":"17","author":"Gupta","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025072913330721000_7.10.e008797.30","unstructured":"World Bank . World bank country and lending groups, 2021. Available: https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups [Accessed 10 Jul 2021]."},{"key":"2025072913330721000_7.10.e008797.31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30442-3"},{"key":"2025072913330721000_7.10.e008797.32","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31173-9"},{"key":"2025072913330721000_7.10.e008797.33","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01500-z"},{"key":"2025072913330721000_7.10.e008797.34","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/s41416-021-01452-4","article-title":"Mortality of patients with solid and haematological cancers presenting with symptoms of COVID-19 with vs without detectable SARS-COV-2: a French nationwide prospective cohort study","volume":"125","author":"Assaad","year":"2021","journal-title":"Br J Cancer"},{"key":"2025072913330721000_7.10.e008797.35","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-4642(21)00066-3","article-title":"Children and young people remain at low risk of COVID-19 mortality","volume":"5","author":"Bhopal","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"2025072913330721000_7.10.e008797.36","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejca.2014.11.011","article-title":"Mortality within 30 days following systemic anti-cancer therapy, a review of all cases over a 4 year period in a tertiary cancer centre","volume":"51","author":"Khoja","year":"2015","journal-title":"Eur J Cancer"},{"key":"2025072913330721000_7.10.e008797.37","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S1470-2045(16)30383-7","article-title":"30-Day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study","volume":"17","author":"Wallington","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025072913330721000_7.10.e008797.38","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00030-2018","article-title":"30-Day mortality after the start of systemic anticancer therapy for lung cancer: is it really a useful performance indicator?","volume":"4","author":"Burgers","year":"2018","journal-title":"ERJ Open Res"},{"key":"2025072913330721000_7.10.e008797.39","unstructured":"Department of Health . Improving Outcomes: A Strategy for Cancer; 2011."},{"key":"2025072913330721000_7.10.e008797.40","unstructured":"Mort D , Lansdown M , Smith N , et al . For better, for worse? 2008."},{"key":"2025072913330721000_7.10.e008797.41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-322909"},{"key":"2025072913330721000_7.10.e008797.42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-0973"},{"key":"2025072913330721000_7.10.e008797.43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.8719"},{"key":"2025072913330721000_7.10.e008797.44","doi-asserted-by":"publisher","DOI":"10.1258\/jrsm.2011.110180"},{"key":"2025072913330721000_7.10.e008797.45","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41576-021-00360-w","article-title":"Testing at scale during the COVID-19 pandemic","volume":"22","author":"Mercer","year":"2021","journal-title":"Nat Rev Genet"},{"key":"2025072913330721000_7.10.e008797.46","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejca.2020.05.015","article-title":"A review of the International early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries","volume":"135","author":"Belkacemi","year":"2020","journal-title":"Eur J Cancer"},{"key":"2025072913330721000_7.10.e008797.47","doi-asserted-by":"crossref","first-page":"E249","DOI":"10.1093\/neuros\/nyab273","article-title":"Letter: is the Stupp protocol an expensive and Unsustainable standard of care for glioblastoma in low- and middle-income country settings? A call to action!","volume":"89","author":"Adegboyega","year":"2021","journal-title":"Neurosurgery"},{"key":"2025072913330721000_7.10.e008797.48","unstructured":"Richards M . Children\u2019s Cancer Services: A review on behalf of NHS England 2019\/20, 2020. NHS England. Available: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2020\/01\/board-meeting-item-9-update-on-specialised-services-c-appendix-2.pdf [Accessed 08 Dec 2021]."}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2022-008797","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T20:33:17Z","timestamp":1753821197000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2022-008797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":48,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,19]]},"published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1136\/bmjgh-2022-008797"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2022-008797","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}